

**ABSTRACT**

**PHARMACEUTICAL COMPOSITION FOR ORAL USE COMPRISING AN ACTIVE PRINCIPLE LIABLE TO UNDERGO A LARGE FIRST INTESTINAL PASSAGE EFFECT**

5 Use of an oral pharmaceutical composition to reduce the intestinal passage effect on the active principle contained in, the said composition being in the form of  
10 a system which is self-microemulsifying on contact with an aqueous phase, comprising:

- a therapeutically effective amount of the said active principle;
- a lipophilic phase comprising a mixture of glycerol mono-, di- and triesters and of PEG mono- and diesters with at least one fatty acid chosen from the group comprising C<sub>8</sub>-C<sub>18</sub> fatty acids;
- a surfactant phase comprising a mixture of glycerol mono-, di- and triesters and of PEG mono- and diesters with caprylic acid (C<sub>8</sub>) and capric acid (C<sub>10</sub>);
- a co-surfactant phase comprising at least one ester of a polyvalent alcohol with at least one fatty acid chosen from the group comprising caprylic esters of propylene glycol, lauric esters of propylene glycol and oleic esters of polyglycerol,
- the ratio TA/CoTA being between 0.2 and 6.